Equities Analysts Offer Predictions for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at Wedbush lifted their FY2025 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Wednesday, October 29th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($3.56) for the year, up from their prior forecast of ($3.85). Wedbush has a “Outperform” rating and a $35.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q4 2025 earnings at ($1.16) EPS, FY2026 earnings at ($4.84) EPS, FY2027 earnings at ($3.54) EPS, FY2028 earnings at ($1.08) EPS and FY2029 earnings at $1.97 EPS.

RCUS has been the subject of several other reports. Wells Fargo & Company lifted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Citigroup lifted their target price on Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, The Goldman Sachs Group lifted their target price on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $28.44.

Arcus Biosciences Stock Down 2.5%

Shares of RCUS opened at $19.70 on Friday. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $22.11. The company has a market cap of $2.13 billion, a PE ratio of -5.73 and a beta of 0.77. The business has a fifty day moving average of $13.95 and a 200 day moving average of $10.73. The company has a quick ratio of 4.50, a current ratio of 3.65 and a debt-to-equity ratio of 0.22.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.Arcus Biosciences’s revenue was down 45.8% on a year-over-year basis. During the same period last year, the company earned ($1.00) earnings per share.

Insider Transactions at Arcus Biosciences

In other news, COO Jennifer Jarrett sold 37,792 shares of the firm’s stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $15.05, for a total transaction of $568,769.60. Following the transaction, the chief operating officer owned 214,232 shares in the company, valued at approximately $3,224,191.60. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Juan C. Jaen sold 77,840 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $20.90, for a total value of $1,626,856.00. Following the transaction, the president owned 1,091,374 shares in the company, valued at approximately $22,809,716.60. This represents a 6.66% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 156,561 shares of company stock worth $2,916,931. Corporate insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares during the last quarter. CWM LLC grew its stake in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after purchasing an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after purchasing an additional 6,191 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after purchasing an additional 5,476 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.